EUVIMEDEUVIMED entdecken
Crossref

Trigger Type and Breakthrough Cardiac Events in Inherited Arrhythmia Syndromes After Left Cardiac Sympathetic Denervation

Vanessa Karlinski Vizentin, Iuri Ferreira Felix, Sahej Bains, Raquel Neves, J Martijn Bos, John R Giudicessi, Stephanie Polites, Michael J Ackerman

JACC: Clinical Electrophysiology · 2026

DOI: 10.1016/j.jacep.2026.03.019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Clinical Electrophysiology, 2026. Verfasst von Vanessa Karlinski Vizentin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Windland Smith Rice Sudden Death Genomics Laboratory, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Min…. Hauptthemen laut MEDLINE: Sympathectomy, Long QT Syndrome, Tachycardia, Ventricular. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Left cardiac sympathetic denervation (LCSD) confers a strong antifibrillatory effect and provides significant therapeutic efficacy for patients with genetic heart diseases, especially long QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT). We hypothesize that LCSD's efficacy may differ among patients experiencing adrenergic (AD) vs nonadrenergic (non-AD) triggered symptoms before LCSD. OBJECTIVES: This study sought to evaluate the association between AD and non-AD triggered events and the subsequent risk of breakthrough cardiac events (BCEs) after LCSD. METHODS: A retrospective review of all previously symptomatic patients with either LQTS or CPVT who underwent LCSD at our institution since 2005 was performed. Data from electronic medical records was abstracted for cardiac event (CE) trigger type (AD or non-AD) before and after LCSD. CEs and BCEs were defined as arrhythmogenic syncope, seizure, appropriate ventricular fibrillation-terminating therapies, and sudden cardiac arrest or death. RESULTS: Among 154 pre-LCSD symptomatic patients (mean age at diagnosis: 15 ± 12 years; follow-up after LCSD: 5.9 ± 4.2 years) with LQTS (n = 105; 68%) or CPVT (n = 49; 32%), 49 patients (32%) had >1 BCE. Post-LCSD BCEs were significantly higher in patients with non-AD triggered CE (n = 30/56; 54%)) compared with patients with AD-triggered CE (n = 19/98; 19%; P < 0.0001). The subset analysis found fewest BCEs in LQT1 patients with AD triggers (OR: 0.24, P < 0.0001). To date, no BCEs have occurred in LQT2, LQT3, or LQT Minor patients with pre-LCSD AD-triggered CEs. CONCLUSIONS: There is a marked pre-LCSD phenotypic determinant of LCSD's therapeutic efficacy. Independently from underlying genotype, patients with adrenergic triggers associated with their pre-LCSD symptoms had a greater reduction in disease-mediated BCEs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SympathectomyLong QT SyndromeTachycardia, VentricularHumansFemaleRetrospective StudiesAdolescentMalePolymorphic Catecholaminergic Ventricular TachycardiaChildYoung AdultAdultDeath, Sudden, CardiacHeart

Stichwörter der Autor:innen

adrenergiccatecholaminergic polymorphic ventricular tachycardialeft cardiac sympathetic denervationlong QT syndrome

Autor:innen und Institutionen

  • Windland Smith Rice Sudden Death Genomics Laboratory, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: https://twitter.com/VizentinVanessa.
  • Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Windland Smith Rice Sudden Death Genomics Laboratory, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA; Medical Scientist Training Program, Mayo Clinic Alix Scho…
  • Windland Smith Rice Sudden Death Genomics Laboratory, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
  • Windland Smith Rice Sudden Death Genomics Laboratory, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA; Division of Pediatric Cardiology, Department of Pediatric…
  • Windland Smith Rice Sudden Death Genomics Laboratory, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA; Division of Heart Rhythm Services, Windland Smith Rice Ge…

Zitieren

APA

Vizentin, V. K., Felix, I. F., Bains, S., Neves, R., Bos, J. M., Giudicessi, J. R., Polites, S., & Ackerman, M. J. (2026). Trigger Type and Breakthrough Cardiac Events in Inherited Arrhythmia Syndromes After Left Cardiac Sympathetic Denervation. JACC: Clinical Electrophysiology. https://doi.org/10.1016/j.jacep.2026.03.019

Vancouver

Vizentin VK, Felix IF, Bains S, Neves R, Bos JM, Giudicessi JR, et al. Trigger Type and Breakthrough Cardiac Events in Inherited Arrhythmia Syndromes After Left Cardiac Sympathetic Denervation. JACC: Clinical Electrophysiology. 2026. doi:10.1016/j.jacep.2026.03.019

BibTeX
@article{Vizentin2026,
  author = {Vizentin, Vanessa Karlinski and Felix, Iuri Ferreira and Bains, Sahej and Neves, Raquel and Bos, J Martijn and Giudicessi, John R and Polites, Stephanie and Ackerman, Michael J},
  title = {Trigger Type and Breakthrough Cardiac Events in Inherited Arrhythmia Syndromes After Left Cardiac Sympathetic Denervation},
  journal = {JACC: Clinical Electrophysiology},
  year = {2026},
  doi = {10.1016/j.jacep.2026.03.019}
}
Kostenlos starten →